Queen's University at Kingston, commonly known as Queen's University or simply Queen's, is a public research university in Kingston, Ontario, Canada. Queen's holds more than 1,400 hectares of land throughout Ontario and owns Herstmonceux Castle in East Sussex, England.

During the past decade, Centre for Applied Urological Research conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 7 clinical trials were completed, i.e. on average, 175% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 4 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre for Applied Urological Research" #1 sponsor was "Queen's University" with 8 trials, followed by "Pfizer" with 4 trials sponsored, "Allergan" with 2 trials sponsored, "Lawson Health Research Institute" with 2 trials sponsored and "AEterna Zentaris" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre for Applied Urological Research" #1 collaborator was "TARIS Biomedical, Inc." with 2 trials as a collaborator, "Allergan" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Boston Scientific Corporation" with 1 trials as a collaborator and "Gyrus ACMI, Inc." with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Centre for Applied Urological Research" are "BPH" (2 trials), "Benign Prostatic Hyperplasia" (2 trials), "Bladder Neoplasms" (2 trials), "Interstitial Cystitis" (2 trials) and "Prostate Cancer" (2 trials). Many other conditions were trialed in "Centre for Applied Urological Research" in a lesser frequency.

Most popular intervention types in "Centre for Applied Urological Research" are "Drug" (14 trials), "Procedure" (4 trials), "Other" (3 trials), "Biological" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Tanezumab" (2 trials), "Bacillus Calmette-Guerin" (1 trials), "Bipolar Transurethral Resection of the Prostate" (1 trials) and "Botox" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centre for Applied Urological Research" are 11 trials for "Male" genders, 8 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Centre for Applied Urological Research". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Centre for Applied Urological Research, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Centre for Applied Urological Research, 2 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".